Items where Author is "Osipenko, Leeza"

Number of items: 11.
  • Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors. (2023) Jentzsch, Valerie and Osipenko, Leeza and Scannell, Jack W. and Hickman, John A. picture_as_pdf
  • A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. (2018) Anderson, Michael and Naci, Huseyin and Morrison, Deborah and Osipenko, Leeza and Mossialos, Elias
  • Assessment of devices, diagnostics and digital technologies: a review of NICE medical technologies guidance. Crispi, Francisca and Naci, Huseyin and Barkauskaite, Eva and Osipenko, Leeza and Mossialos, Elias picture_as_pdf
  • Assessment of quality of data submitted for NICE technology appraisals over two decades. Osipenko, Leeza and Ul-Hasan, Saba Ajwat and Winberg, Debra and Prudyus, Kseniia and Kousta, Marina and Rizoglou, Artemis and Rustignoli, Isabella and Van Der Maas, Laurens picture_as_pdf
  • Audit of data redaction practices in NICE technology appraisals from 1999 to 2019. Osipenko, Leeza picture_as_pdf
  • Blockchain's potential to improve clinical trials-an essay by Leeza Osipenko. Osipenko, Leeza picture_as_pdf
  • Does industry really develop less medicine with clinical benefit?—Reply. Osipenko, Leeza
  • The Locked-down:we need more than headline statistics to understand the impact of Covid-19. Osipenko, Leeza picture_as_pdf
  • Provenance and clinical benefit of medicines introduced to the French market, 2008 to 2018. Osipenko, Leeza and Potey, Philippe and Perez, Bernardo and Kupryjanczuk, Alexandra and Angelov, Filip and Schuster, Alexandra and Mossialos, Elias picture_as_pdf
  • The early impact of the global lockdown on post-secondary students and staff:a global, descriptive study. Nowrouzi-Kia, Behdin and Osipenko, Leeza and Eftekhar, Parvin and Othman, Nasih and Alotaibi, Sultan and Schuster, Alexandra M and Sun Suh, Hae and Duncan, Andrea picture_as_pdf
  • The origin of first‐in‐class drugs:innovation versus clinical benefit. Osipenko, Leeza and Potey, Philippe and Perez, Bernardo and Angelov, Filip and Parvanova, Iva and Ul‐hasan, Saba and Mossialos, Elias picture_as_pdf